1. Home
  2. ADAG vs INTT Comparison

ADAG vs INTT Comparison

Compare ADAG & INTT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adagene Inc.

ADAG

Adagene Inc.

HOLD

Current Price

$3.64

Market Cap

254.4M

Sector

Health Care

ML Signal

HOLD

Logo inTest Corporation

INTT

inTest Corporation

HOLD

Current Price

$18.55

Market Cap

234.0M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADAG
INTT
Founded
2011
1981
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Semiconductors
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
254.4M
234.0M
IPO Year
2020
1997

Fundamental Metrics

Financial Performance
Metric
ADAG
INTT
Price
$3.64
$18.55
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
2
Target Price
$8.25
$13.50
AVG Volume (30 Days)
186.8K
299.3K
Earning Date
04-01-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.06
Revenue
N/A
$66,801,000.00
Revenue This Year
N/A
$15.82
Revenue Next Year
N/A
$9.10
P/E Ratio
N/A
$290.00
Revenue Growth
N/A
66.06
52 Week Low
$1.44
$6.63
52 Week High
$4.75
$20.00

Technical Indicators

Market Signals
Indicator
ADAG
INTT
Relative Strength Index (RSI) 50.78 57.98
Support Level $3.29 $7.55
Resistance Level $4.09 $19.91
Average True Range (ATR) 0.31 1.34
MACD 0.00 0.07
Stochastic Oscillator 39.47 92.84

Price Performance

Historical Comparison
ADAG
INTT

About ADAG Adagene Inc.

Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.

About INTT inTest Corporation

inTest Corp is a supplier of test and process technology solutions for use in manufacturing and testing across a wide range of markets, including Semi, Auto/EV, Defense/Aerospace, Industrial, Life Sciences, Safety/Security, and Other. The Company has three operating segments, which are also its reportable segments and reporting units: Electronic Test, which generates the majority of its revenue and includes semiconductor test equipment, flying probe, and in-circuit testers; Environmental Technologies, which includes thermal test, process, and storage products; and Process Technologies, which includes induction heating and video imaging products. The Company generates the maximum revenue from the U.S.

Share on Social Networks: